HappeningToo topic
Ocrelizumab reports
Browse community reports connected to Ocrelizumab. These reports can show that other people are describing similar experiences, but they do not prove that Ocrelizumab caused a symptom or reaction.
⚕️ Medicine safety note
Community reports do not prove causation, cannot be used to estimate how common a reaction is, and are not medical advice.
40 problems
Abdominal Pain Upper while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and abdominal pain upper appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Alopecia while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and alopecia appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Anxiety while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and anxiety appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Back Pain while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and back pain appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Chills while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and chills appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Constipation while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and constipation appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Cough while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and cough appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Diarrhea while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and diarrhea appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Dizziness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and dizziness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Fatigue while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and fatigue appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Feeling Abnormal while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and feeling abnormal appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Feeling Hot while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and feeling hot appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Flushing while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and flushing appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Headache while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and headache appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Heart Rate Increased while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and heart rate increased appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Hives while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and hives appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Hypotension while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and hypotension appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Influenza Like Illness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and influenza like illness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Insomnia while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and insomnia appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Itching while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and itching appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Malaise while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and malaise appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Migraine while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and migraine appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Muscle Spasms while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and muscle spasms appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Muscular Weakness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and muscular weakness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Myalgia while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and myalgia appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Nausea while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and nausea appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Oropharyngeal Pain while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and oropharyngeal pain appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Pain while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and pain appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Palpitations while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and palpitations appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Rash while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and rash appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Shortness of breath while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and shortness of breath appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Skin redness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and skin redness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Sleepiness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and sleepiness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Tingling or pins and needles while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and tingling or pins and needles appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Tremor while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and tremor appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vision Blurred while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and vision blurred appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Vomiting while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and vomiting appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weakness while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and weakness appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weight Decreased while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and weight decreased appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →
Weight Increased while using Ocrelizumab
FDA FAERS contains adverse-event reports in which Ocrelizumab and weight increased appear together. This does not establish that Ocrelizumab caused the reported reaction and cannot be used to estimate how often it occurs.
View reports →